One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics

• Ngā kaituhi matua: Wei Chen (Author), Fan Yang (Author), Carole Wang (Author), Jatin Narula (Author), Edward Pascua (Author), Irene Ni (Author), Sheng Ding (Author), Xiaodi Deng (Author), Matthew Ling-Hon Chu (Author), Amber Pham (Author), Xiaoyue Jiang (Author), Kevin C. Lindquist (Author), Patrick J. Doonan (Author), Tom Van Blarcom (Author), Yik Andy Yeung (Author), Javier Chaparro-Riggers (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-binding arm distance, with our bispecific IgG platform...